Prostate cancer: Moderate hypofractionated radiotherapy - not yet a standard of care

Affiliations

¹ Department of Radiation Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 North West 12th Avenue, Suite 1500, Miami, Florida 33136, USA.

Comment

Alan Pollack et al. Nat Rev Clin Oncol. 2016 Nov.

. 2016 Nov;13(11):655-656.

doi: 10.1038/nrclinonc.2016.147. Epub 2016 Sep 20.

¹ Department of Radiation Oncology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, 1475 North West 12th Avenue, Suite 1500, Miami, Florida 33136, USA.

No abstract available

Comment on

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O'Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E; CHHiP Investigators. Dearnaley D, et al. Lancet Oncol. 2016 Aug;17(8):1047-1060. doi: 10.1016/S1470-2045(16)30102-4. Epub 2016 Jun 20. Lancet Oncol. 2016. PMID: 27339115 Free PMC article. Clinical Trial.